Researchers in Montpellier have developed a prototype blood test designed to detect colorectal cancer with high sensitivity, potentially offering a less invasive alternative to traditional screening methods like colonoscopies. By identifying specific biomarkers circulating in the bloodstream, this diagnostic tool aims to improve early detection rates for a malignancy that remains a leading cause of cancer-related mortality globally. The development, led by teams associated with the University of Montpellier and local clinical research centers, follows years of investigation into liquid biopsy technologies.
Colorectal cancer, which affects the colon or rectum, is frequently asymptomatic in its early stages, often leading to late-stage diagnoses when treatment efficacy is reduced. According to the World Health Organization, early detection is critical for patient survival, yet participation in existing screening programs, such as fecal immunochemical tests (FIT) or colonoscopies, remains suboptimal in many regions due to patient discomfort or procedural barriers. This new diagnostic approach seeks to increase screening uptake by utilizing a simple blood draw to flag the presence of tumor-derived genetic material.
How the blood test functions
The diagnostic mechanism relies on the analysis of circulating tumor DNA (ctDNA) and specific protein markers that are often shed into the bloodstream by colorectal tumors. When cells undergo apoptosis or necrosis, they release fragments of their genome into the plasma. Scientists in Montpellier have refined techniques to isolate and amplify these rare sequences, even when they are present in minute quantities during the early stages of disease development, as outlined in recent reports by the French National Institute of Health and Medical Research (Inserm).
Unlike stool-based tests that look for occult blood, the blood-based assay targets molecular signatures specific to the oncogenic transformation of colon cells. By focusing on these biomarkers, the researchers aim to reduce the number of false positives often associated with non-specific screening tools. The transition from laboratory prototype to clinical application involves rigorous validation phases to ensure the test meets the sensitivity and specificity standards required for public health implementation.
Clinical validation and next steps
Before this test can be integrated into routine clinical practice, it must undergo large-scale prospective trials to confirm its diagnostic accuracy across diverse populations. Regulatory bodies, such as the European Medicines Agency (EMA), require extensive data to prove that a new diagnostic tool provides a clear benefit over existing standards of care. These trials typically assess the test’s ability to detect precancerous lesions, such as advanced adenomas, as well as early-stage invasive cancers.
The research group in Montpellier is currently working on optimizing the analytical platform to ensure it can be standardized for hospital laboratories. As noted in guidance from the American Cancer Society regarding emerging diagnostics, the ultimate goal for any new screening test is to demonstrate a reduction in mortality through earlier intervention without causing unnecessary anxiety or follow-up procedures for patients with benign findings.
Impact on public health screening
The potential implementation of a blood-based screening test could significantly shift the current landscape of oncology. By removing the physical and psychological barriers associated with invasive colonoscopies, healthcare systems may see an increase in the number of individuals who adhere to recommended screening schedules. This is particularly relevant for populations currently categorized as “hard-to-reach” or those who have historically declined standard screening invitations.
However, medical experts emphasize that these tests are intended to complement, not replace, the gold standard of colonoscopy. While a blood test might act as a “gatekeeper” to identify those who require a diagnostic colonoscopy, the latter remains the only method capable of both detecting and removing precancerous polyps during the same procedure. The European Centre for Disease Prevention and Control continues to stress that the most effective strategy for managing colorectal cancer remains a combination of population-wide screening and lifestyle modifications, such as healthy diet and regular physical activity.
Future outlooks
The Montpellier team is expected to publish further results from their ongoing validation studies in peer-reviewed journals in the coming months. These publications will be essential for the scientific community to assess the reproducibility and reliability of the test. As the project advances, the next major checkpoint will involve the application for CE marking in Europe, which would allow for the clinical use of the device within the European Union.
Readers interested in the latest updates on cancer screening protocols are encouraged to consult their primary care physicians or visit the official portals of national health authorities. For those looking to follow the progress of this specific diagnostic development, tracking announcements from the University of Montpellier and associated health research networks will provide the most accurate, verified information as the project moves toward regulatory review.
Have you or a loved one been affected by colorectal cancer, or are you interested in the latest developments in early detection? Share your thoughts and questions in the comments section below.
Related reading